EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Natriuretic peptide pathways in heart failure: further therapeutic possibilities

S Jeson Sangaralingham, Michaela Kuhn, Valentina Cannone, Horng H Chen iD, John C Burnett

Cardiovascular Research · 03.02.2023 · 118 (18) · 3416-3433

DOI: 10.1093/cvr/cvac125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 25.08.2022. Verfasst von S Jeson Sangaralingham und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiorenal Research Laboratory, Department of Cardiovascular Medicine, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Receptors, Atrial Natriuretic Factor, Heart Failure. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The discovery of the heart as an endocrine organ resulted in a remarkable recognition of the natriuretic peptide system (NPS). Specifically, research has established the production of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) from the heart, which exert pleiotropic cardiovascular, endocrine, renal, and metabolic actions via the particulate guanylyl cyclase A receptor (GC-A) and the second messenger, cGMP. C-type natriuretic peptide (CNP) is produced in the endothelium and kidney and mediates important protective auto/paracrine actions via GC-B and cGMP. These actions, in part, participate in the efficacy of sacubitril/valsartan in heart failure (HF) due to the augmentation of the NPS. Here, we will review important insights into the biology of the NPS, the role of precision medicine, and focus on the phenotypes of human genetic variants of ANP and BNP in the general population and the relevance to HF. We will also provide an update of the existence of NP deficiency states, including in HF, which provide the rationale for further therapeutics for the NPS. Finally, we will review the field of peptide engineering and the development of novel designer NPs for the treatment of HF. Notably, the recent discovery of a first-in-class small molecule GC-A enhancer, which is orally deliverable, will be highlighted. These innovative designer NPs and small molecule possess enhanced and novel properties for the treatment of HF and cardiovascular diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Atrial Natriuretic FactorHeart FailureHumansNatriuretic PeptidesNatriuretic Peptide, BrainHeartNatriuretic Peptide, C-TypeGuanylate CyclaseVasodilator AgentsAtrial Natriuretic Factor

Stichwörter der Autor:innen

Guanylyl cyclase drug discoveryHeart failureNatriuretic peptidesSmall molecules

Substanzen

Receptors, Atrial Natriuretic FactorNatriuretic PeptidesNatriuretic Peptide, BrainNatriuretic Peptide, C-TypeGuanylate CyclaseVasodilator AgentsAtrial Natriuretic Factor

Autor:innen und Institutionen

  • Cardiorenal Research Laboratory, Department of Cardiovascular Medicine, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.
  • Department of Physiology and Biomedical Engineering, Mayo Clinic 200 1st St SW, Rochester MN 55905, USA.
  • Institute of Physiology, University of Wuerzburg, Roentgenring 9, D-97070 Wuerzburg, Germany.
  • Department of Medicine and Surgery, University of Parma, Via Gramsci 14, 43126 Parma, Italy.

ORCID-Profile: Horng H Chen

Förderung

  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • National Institutes of Health
  • American Heart Association
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Sangaralingham, S. J., Kuhn, M., Cannone, V., Chen, H. H., & Burnett, J. C. (2023). Natriuretic peptide pathways in heart failure: further therapeutic possibilities. Cardiovascular Research, 118(18), 3416-3433. https://doi.org/10.1093/cvr/cvac125

Vancouver

Sangaralingham SJ, Kuhn M, Cannone V, Chen HH, Burnett JC. Natriuretic peptide pathways in heart failure: further therapeutic possibilities. Cardiovascular Research. 2023;118(18):3416-3433. doi:10.1093/cvr/cvac125

BibTeX
@article{Sangaralingham2023,
  author = {Sangaralingham, S Jeson and Kuhn, Michaela and Cannone, Valentina and Chen, Horng H and Burnett, John C},
  title = {Natriuretic peptide pathways in heart failure: further therapeutic possibilities},
  journal = {Cardiovascular Research},
  year = {2023},
  volume = {118},
  number = {18},
  pages = {3416--3433},
  doi = {10.1093/cvr/cvac125}
}
Kostenlos starten →